Insmed Incorporated (INSM) Price Target Raised to $211 at BofA

Core Insights - BofA raised the price target for Insmed Incorporated (INSM) to $211 from $209, maintaining a Buy rating, citing positive guidance for Brinsupri sales in fiscal 2026 of at least $1 billion as a key development [1] - Morgan Stanley also increased its price target for Insmed to $166 from $162, reiterating an Equal Weight rating, noting that the management's revenue outlook for Brinsupri aligns with expectations and suggests potential market expansion [2] - Insmed reported total revenues of $606.4 million for the full year 2025, with Brinsupri revenues of $172.7 million and Q4 revenues of $144.6 million, while ARIKAYCE generated $119.2 million in Q4 and $433.8 million for the full year, indicating a 19% annual growth [3] Company Overview - Insmed Incorporated, founded in 1988 and headquartered in Bridgewater, New Jersey, is a global biopharmaceutical firm focused on developing therapies for rare and serious diseases, with key assets including brensocatib and Treprostinil Palmitil Inhalation Powder [4]